All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Aman, 2021 0.51 [0.27; 0.96]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.14 [0.02; 0.96]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tang X, 2020 0.98 [0.93; 1.02]
0.76 [0.65 ; 0.88 ] ACTT-2 (Kalil), 2020, Aman, 2021, Bennett-Guerrero, 2021, CAN-COVID, 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lanzoni, 2021, Metcovid, 2020, NCT04412772 (ARCHITECTS), 0, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tang X, 2020 22 45% 9,821 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
Lopardo, 2021 0.65 [0.35; 1.22]
0.79 [0.50 ; 1.24 ] BACC Bay Tocilizumab Trial, 2020, Lopardo, 2021 2 0% 483 moderate not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Aman, 2021 0.51 [0.27; 0.96]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CCAP-2, 2021 2.03 [0.61; 6.77]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
EMPACTA, 2020 1.13 [0.54; 2.40]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04442191, 2021 0.11 [0.00; 143.68]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Salehzadeh, 2020 1.00 [0.02; 51.41]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tang X, 2020 0.98 [0.93; 1.02]
0.78 [0.69 ; 0.89 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, Aman, 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAPE-COVID, 2020, CCAP-2, 2021, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Metcovid, 2020, NCT04412772 (ARCHITECTS), 0, NCT04442191, 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Salehzadeh, 2020, SAVE-MORE, 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020 39 34% 15,193 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
0.80 [0.65 ; 0.98 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, COV-BARRIER, 2021, COVACTA (Rosas), 2020, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021 12 31% 7,472 moderate low clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
Libster, 2020 0.52 [0.29; 0.94]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
0.66 [0.47 ; 0.93 ] BACC Bay Tocilizumab Trial, 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, EMPACTA, 2020, Libster, 2020, SAVE-MORE, 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020 9 73% 3,055 low not evaluable clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
EMPACTA, 2020 1.15 [0.90; 1.47]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
1.10 [1.04 ; 1.17 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020 20 2% 8,299 moderate low clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Tang X, 2020 1.33 [0.57; 3.11]
1.22 [1.07 ; 1.41 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Tang X, 2020 5 12% 3,714 low not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
O’Donnell, 2021 1.38 [0.73; 2.61]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.47 [1.11 ; 1.93 ] Bennett-Guerrero, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020 7 0% 962 moderate not evaluable clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
0.98 [0.76 ; 1.26 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022 2 0% 899 moderate not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
EMPACTA, 2020 1.15 [0.90; 1.47]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Tang X, 2020 1.04 [0.67; 1.62]
1.08 [1.00 ; 1.16 ] ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, EMPACTA, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Tang X, 2020 9 0% 3,225 moderate not evaluable death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.72 [0.62 ; 0.83 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020 9 0% 3,559 moderate not evaluable hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
EMPACTA, 2020 1.16 [0.90; 1.49]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.13 [0.96 ; 1.32 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, EMPACTA, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 6 36% 2,410 moderate serious hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Metcovid, 2020 1.19 [0.56; 2.49]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.75 [0.59 ; 0.96 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Metcovid, 2020, O’Donnell, 2021, PlasmAr, 2020, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 9 0% 2,818 low not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Tang X, 2020 1.78 [1.06; 3.00]
1.18 [0.54 ; 2.54 ] Jagannathan, 2020, Tang X, 2020 2 83% 206 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Tang X, 2020 1.78 [1.06; 3.00]
1.18 [0.54 ; 2.54 ] Jagannathan, 2020, Tang X, 2020 2 83% 206 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Tang X, 2020 1.00 [0.13; 7.45]
0.56 [0.36 ; 0.86 ] COVACTA (Rosas), 2020, Libster, 2020, Lopardo, 2021, Tang X, 2020 4 0% 678 moderate not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Lanzoni, 2021 3.46 [1.05; 11.35]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
1.19 [0.99 ; 1.42 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Lanzoni, 2021, Synairgen SG016, 2020 6 33% 1,254 low serious composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Shi, 2020 1.08 [0.04; 32.96]
0.92 [0.77 ; 1.10 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COVACTA (Rosas), 2020, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020 12 15% 3,647 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.74 [0.49 ; 1.11 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020 3 57% 1,575 low not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Jagannathan, 2020 1.33 [0.63; 2.78]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Shi, 2020 0.88 [0.38; 2.03]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
1.07 [0.84 ; 1.38 ] COVACTA (Rosas), 2020, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 9 15% 1,851 moderate serious 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-15 04:15 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290